This afternoon, we released a 60-page Executive Informational Overview on New Hampshire-based Boston Therapeutics, Inc. (BTHE-OTC).
Boston Therapeutics, Inc. (or “the Company”) develops products to address the diabetes and inflammatory disease markets using complex carbohydrate chemistry (CCC) technology. The Company’s portfolio includes two development-stage pharmaceutical candidates as well as a marketed over-the-counter (OTC) dietary supplement. The lead pharmaceutical candidate, BTI320 (formerly PAZ320), is a Phase II/III non-systemic, non-toxic, carbohydrate-based chewable tablet being evaluated as a therapy for Type 2 diabetes in patients currently taking metformin. The compound inhibits enzymes that release glucose from complex carbohydrates in foods during digestion—reducing the amount of glucose released from digested complex carbohydrates.
Boston Therapeutics’ second pipeline candidate is Ipoxyn™ (and a veterinary analog of Ipoxyn™, called OxyFex™), which is a carbohydrate-based intravenous solution in development to treat hypoxic conditions caused by a lack of oxygen to living tissue, such as lower-limb ischemia stemming from severe diabetes. The Ipoxyn™ molecule, which is 5,000 times smaller than a red blood cell (RBC), works by picking up oxygen in the lungs and offloading it to tissue that has been oxygen-deprived. The Company is positioned to benefit from two simultaneous paths to market—OTC and pharmaceutical drug development.
Key Points About Boston Therapeutics’ Business
In a Phase IIa trial, BTI320 showed a 40% reduction in elevation of post-meal blood sugar with no serious adverse events. Enrollment in Phase IIb is underway, with the Company preparing for an IND filing with the FDA for a Phase III study.